CAR-NK cells: A promising cellular immunotherapy for cancer
Name
1-s2.0-S2352396420303510-main.pdf
Description
Published version
Size
1.19 MB
Format
Unknown
Checksum (MD5)
2d6c97fa4399f2709a33ecf6e81ce271
Author(s)
Xie, Guozhu
Dong, Han
Liang, Yong
Ham, James Dongjoo
Rizwan, Romee
Chen, Jianzhu
Date Issued
September 2020
Journal
EBioMedicine
Publisher
Elsevier BV
Version
Final published version
Abstract
© 2020 The Author(s) Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid growing interest in developing CAR-engineered NK (CAR-NK) cells for cancer therapy. Compared to CAR-T cells, CAR-NK cells could offer some significant advantages, including: (1) better safety, such as a lack or minimal cytokine release syndrome and neurotoxicity in autologous setting and graft-versus-host disease in allogenic setting, (2) multiple mechanisms for activating cytotoxic activity, and (3) high feasibility for ‘off-the-shelf’ manufacturing. CAR-NK cells could be engineered to target diverse antigens, enhance proliferation and persistence in vivo, increase infiltration into solid tumours, overcome resistant tumour microenvironment, and ultimately achieve an effective anti-tumour response. In this review, we focus on recent progress in genetic engineering and clinical application of CAR-NK cells, and discuss current challenges and future promise of CAR-NK cells as a novel cellular immunotherapy in cancer.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.ebiom.2020.102975
